Insulin icodec
| Clinical data | |
|---|---|
| Trade names | Aweeqli |
| Routes of administration | subcutaneous |
| ATC code | |
| Pharmacokinetic data | |
| Elimination half-life | 196 hours |
| Identifiers | |
| |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
Insulin icodec (INN/USAN) is an ultralong-acting basal insulin analogue that was developed by Novo Nordisk under the brand name Aweeqli. It has completed Phase 3 trials[1] and has been submitted for regulatory review in the US, Canada, Europe, China, Australia, Switzerland and Brazil.[2] The first decisions are anticipated in H1 2024. It is administered via subcutaneous injection once weekly to help control the blood sugar level of those with diabetes.
It has a plasma half-life more than eight days[3] (compared to 25 hours of the previous longest-acting insulin analogue insulin degludec), making it a once-weekly basal insulin.[4] The substance is composed of two peptide chains, linked by a disulfide bridge. In addition the 21 amino acid residue chain has two internal disulfide bridges and the second chain is 29 residues long.
Glycemic control was non-inferior with once-weekly insulin icodec compared with once-daily insulin glargine U100. (Funded by Novo Nordisk; ONWARDS 1 ClinicalTrials.gov number, NCT04460885. opens in new tab.)
References
- ^ "Molecular and Biological Properties of Insulin Icodec*, a New Insulin Analog Designed to Give a Long Half-Life Suitable for Once-Weekly Dosing".
- ^ "News Details". Novo Nordisk. Retrieved 2023-07-24.
- ^ Kjeldsen, Thomas B.; Hubálek, František; Hjørringgaard, Claudia U.; Tagmose, Tina M.; Nishimura, Erica; Stidsen, Carsten E.; Porsgaard, Trine; Fledelius, Christian; Refsgaard, Hanne H. F.; Gram-Nielsen, Sanne; Naver, Helle; Pridal, Lone; Hoeg-Jensen, Thomas; Jeppesen, Claus Bekker; Manfè, Valentina (2021-07-08). "Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans". Journal of Medicinal Chemistry. 64 (13): 8942–8950. doi:10.1021/acs.jmedchem.1c00257. ISSN 1520-4804. PMID 33944562.
- ^ Kjeldsen TB, Hubálek F, Hjørringgaard CU, Tagmose TM, Nishimura E, Stidsen CE, et al. (July 2021). "Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans". Journal of Medicinal Chemistry. 64 (13): 8942–8950. doi:10.1021/acs.jmedchem.1c00257. PMID 33944562. S2CID 233718893.
- ^ Rosenstock, Julio; Bain, Stephen C.; Gowda, Amoolya; Jódar, Esteban; Liang, Bo; Lingvay, Ildiko; Nishida, Tomoyuki; Trevisan, Roberto; Mosenzon, Ofri (2023-07-27). "Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin". New England Journal of Medicine. 389 (4): 297–308. doi:10.1056/NEJMoa2303208. ISSN 1533-4406. PMID 37356066.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |